RecruitingObservational

Prospective Database of Clinical Outcomes Following Cryotherapy for Ablation of Clinically Localized Prostate Cancer

NCT ID: NCT07184957Sponsor: NYU Langone HealthLast updated: 2025-09-22

Summary

This will be a prospectively maintained research database. The purpose is to record baseline parameters and treatment outcomes following of Cryotherapy for ablation of clinically localized prostate cancer.

Arms & interventions

Outcome measures

Primary

Treatment Complications
Time frame: Up to Year 15
PSA-Progression Free Survival
Length of time following cryotherapy for ablation treatment of prostate cancer that a patient lives without their prostate-specific antigen (PSA) levels rising significantly enough to indicate disease recurrence, or without dying from any cause.
Time frame: Up to Year 15

Eligibility criteria

Sex: MaleAge: 40 Years to 85 YearsHealthy volunteers: No

Inclusion Criteria: * Evidence of focal prostate cancer confined to the prostate based on MRI imaging and prostate biopsy * Patients with clinically localized prostate cancer (no evidence for or concern for metastatic spread of cancer outside of the prostate) will be counseled regarding treatment options. Those selecting focal Cryo prostate ablation will then be offered inclusion into this data collection. Exclusion Criteria: * Men that are not diagnosed with prostate cancer. * Men that are diagnosed with clinically localized prostate cancer, but select other treatment options as their desired treatment.

Study locations (1)

NYU Langone Health

New York, New York, 10016

Recruiting